Role of Vitrectomy in the Treatment of Diabetic Retinopathy
https://doi.org/10.18008/1816-5095-2021-3S-718-726
Abstract
Diabetic retinopathy (DR) is a socially significant disease with a steady tendency to increase, in which there is a high risk of disability due to persistent loss of vision. There are three main pathogenetically substantiated methods of DR treatment: laser coagulation of the retina; intravitreal injections of VEGF inhibitors, steroid drugs; vitreoretinal surgery. In the later stages of DR, vitrectomy is the main method of its complications treating, but there is no clear understanding of the timeliness of this operation. The analysis of the results of original research on this problem is carried out. It has been shown that with the advent of new instruments, modified vitrector, operating microscopes, viewing systems and vitreoretinal combines, vitrectomy led to a change in the paradigm of DR treatment. These advances have resulted in better surgical control and greater precision, while at the same time shorter surgical times and fewer surgical complications. There is a tendency to perform vitrectomy at earlier stages of DR, which has a pathogenetic rationale. This could be a leap forward in the treatment of DR as a preventive measure against the development of proliferative DR.
Keywords
diabetic retinopathy,
nonproliferative diabetic retinopathy,
proliferative diabetic retinopathy,
diabetic macular edema,
DME,
neovascularization of the retina,
neovascularization of the optic nerve,
vitrectomy,
vitreoretinal surgery,
laser coagulation of the retina,
endothelial growth factor,
VEGF,
anti-VEGF therapy
About the Authors
D. V. Petrachkov
Research Institute of Eye Diseases
Russian Federation
Russian Federation
Petrachkov Denis V., PhD, head of the Department of innovative vitreoretinal technologies
Rossolimo str., 11A,B, Moscow, 119021
E. N. Korobov
Research Institute of Eye Diseases
Russian Federation
Russian Federation
Korobov Egor N., PhD, junior researcher of the Department of innovative vitreoretinal technologies
Rossolimo str., 11A,B, Moscow, 119021
D. D. Arzhukhanov
Research Institute of Eye Diseases
Russian Federation
Russian Federation
Arzhukhanov Dmitriy D., postgraduate of the Department of innovative vitreoretinal technologies
Rossolimo str., 11A,B, Moscow, 119021
References
1. International Diabetes Federation. IDF Diabetes Atlas. 9th ed; 2019.
2. Lee R., Wong T.Y., Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17. DOI: 10.1186/s40662-015-0026-2
3. WHO. Global Report on Diabetes; 2016:88. https://www.who.int/publications/i/item/9789241565257
4. Yau J., Rogers S., Kawasaki R. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–564. DOI: 10.2337/dc11-1909
5. International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels:IDF; 2017.
6. Lipatov D.V., Vikulova O.K., Zheleznyakova A.V. Trends in the epidemiology of diabetic retinopathy in Russian Federation according to the federal diabetes register (2013–2016). Diabetes Mellitus. 2018;21(4):230–240 (In Russ.). DOI: 10.14341/DM9797
7. Dedov I.I., Shestakova M.V., Mayorov A.Yu. Standards of specialized diabetes care. Diabetes Mellitus = Sakharnii Diabet 2017;20(1S):1–121 (In Russ.). DOI: 10.14341/DM20171S8
8. Maniadakis N., Konstantakopoulou E. Cost effectiveness of treatments for diabetic retinopathy: a systematic literature review. PharmacoEconomics. 2019;37(8):995– 1010. Accessed April 22, 2019. DOI: 10.1007/s40273-019-00800-w
9. Healthcare in Russia. ed. Shapovala I.N., Nikitinoj S.Yu. Moscow: Rosstat; 2019 (In Russ.).
10. Dedov I.I., Shestakova M.V., Vikulova O.K. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Diabetes Mellitus = Sakharnii Diabet 2017;20(1):13–41 (In Russ.). DOI: 10.14341/DM8664
11. Simo-Servat O., Hernandez C., Simo R. Diabetic retinopathy in the context of patients with diabetes. Ophthalmic Research. 2019;62(4):211–217. DOI: 10.1159/000499541
12. Ivakhnenko O.I., Neroev V.V., Zaytseva O.V. Age-related macular degeneration and diabetic eye lession. Socio-economic aspects. Annals of Ophthalmology = Vestnik oftal’mologii 2021; 137(1):123–129 (In Russ.). DOI: 10.17116/oftalma2021137011123
13. Stitt A., Curtis T., Chen M. The progress in understanding and treatment of diabetic retinopathy. Progress in Retinal and Eye Research. 2016;51:156–186. DOI: 10.1016/j.preteyeres.2015.08.001
14. Ting D., Cheung G., Wong T. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clinical & Experimental Ophthalmology. 2016;44(4):260–277. DOI: 10.1111/ceo.12696
15. Mansour S., Browning D., Wong K. The Evolving Treatment of Diabetic Retinopathy. Clinical Ophthalmology. 2020;14:653–678. Accessed March 19, 2020. DOI: 10.2147/OPTH.S236637
16. Gupta V., Fernando J. Arevalo. Surgical Management of Diabetic Retinopathy. Middle East African Journal of Ophthalmology. 2013;20(4):283–292. DOI: 10.410309749233.120003
17. Lin J., Chang J., Yannuzzi N. Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. Ophthalmology. 2018;125(9):1393–1400. DOI: 10.1016/j.ophtha.2018.02.038
18. Nawaza I., Rezzolaa S., Cancarini A. Human vitreous in proliferative diabetic retinopathy: Characterization and translational implications. Progress in Retinal and Eye Research. 2019;72:100756. DOI: 10.1016/j.preteyeres.2019.03.002
19. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90(2):121–125. DOI: 10.1016/s0161-6420(83)34588-7
20. Hernández C., Simó-Servat A., Bogdanov P., Simó R. Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms. Journal of Endocrinological Investigation. 2017;40(9):925–935. DOI: 10.1007/s40618-017-0648-4
21. Van Geest R., Lesnik-Oberstein S., Tan H. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol. 2012;96(4):587–590. DOI: 10.1136/bjophthalmol-2011-301005
22. Balashevich L.I., Izmajlova A.S. Diabetic ophthalmopathy. SaintPeterburg: Chelovek; 2012 (In Russ.).
23. Cunha-Vaz J. Mechanisms of retinal fluid accumulation and blood-retinal barrier breakdown. Dev. Ophthalmol. 2017;58:11–20. DOI: 10.1159/000455265
24. Coscas G., Cunha-Vaz J., Soubrane G. Macular edema: defnition and basic concepts. Dev. Ophthalmol. 2017;58:1–10. DOI: 10.1159/000455264
25. Zhang X., Zeng H., Bao S. Diabetic macular edema: new concepts in pathophysiology and treatment. Cell Biosci. 2014;4:27. Accessed May 14, 2014. DOI: 10.1186/2045-3701-4-27
26. Daruich A., Matet A., Moulin A. Mechanisms of macular edema: beyond the surface. Prog. Retin. Eye Res. 2018;63:20–68. DOI: 10.1016/j.preteyeres.2017.10.006
27. The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. American Journal of Ophthalmology. 1976;81:383–396. DOI: 10.1016/0002-9394(76)90292-0
28. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98(5Suppl):766–785. DOI: 10.1016/S0161-6420 (13)38011-7
29. Suzuki Y., Adachi K., Maeda N. Proliferative diabetic retinopathy without preoperative pan-retinal photocoagulation is associated with higher levels of intravitreal IL-6 and postoperative infammation. International Journal of Retina and Vitreous. 2020;6:24. Accessed June 8, 2020. DOI: 10.1186/s40942-020-00222-3
30. Budzinskaya M.V., Plyukhova A.A., Toropygin S.G. Modern view on the treatment of wet-AMD patients. Annals of Ophthalmology = Vestnik oftal’mologii 2019;135(5):107–115 (In Russ.). DOI: 10.17116/oftalma2019135051107
31. Ip M.S., Domalpally A., Sun J.K., Ehrlich J.S. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and base-line risk factors for worsening retinopathy. Ophthalmology. 2015;122(2):367–374. DOI: 10.1016/j.ophtha.2014.08.048
32. Bressler S., Odia I., Glassman A. Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR. Net protocol I 5-year report. Retina. 2018;38(10):1896–1904. DOI: 10.1097/IAE.0000000000002302
33. Wang D., Zhao X., Zhang W. Perioperative anti‑vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis. Scientifc Reports. 2020;10(1):18880. Accessed November 3, 2020. DOI: /10.1038/s41598-020-75896-8
34. Tan Y., Fukutomi A., Sun M. Anti-VEGF Crunch Syndrome in Proliferative Diabetic Retinopathy: A Review. Surv Ophthalmol. 2021;S0039-6257(21)00074-6. Accessed March 8, 2021. DOI: 10.1016/j.survophthal.2021.03.001
35. Jiang T., Gu J., Zhang P. The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study. BMC Ophthalmol. 2020;20(1):43. DOI: 10.1186/s12886-020-1321-9
36. Antoszyk A., Glassman A., Beaulieu W. DRCR Retina Network. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: A Randomized Clinical Trial. JAMA. 2020;324(23):2383–2395. DOI: 10.1001/jama.2020.23027
37. Maturi R., Glassman A., Liu D. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol. 2018;136(1):29–38. DOI: 10.1001/jamaophthalmol.2017.4914
38. Iglicki M., Zur D., Busch C. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the ‘DR-Pro-DEX Study’. Acta Diabetol. 2018;55:541–547. DOI: 10.1007/s00592-018-1117-z
39. Wykoff C., Chakravarthy U., Campochiaro P. Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy. Ophthalmology. 2017;124(4):440–449. DOI: 10.1016/j.ophtha.2016.11.034
40. Pessoa B., Coelho J., Correia N. Fluocinolone acetonide intravitreal implant 190 mug (ILUVIEN(R)) in vitrectomized versus nonvitrectomized eyes for the treatment of chronic diabetic macular edema. Ophthalmic Res. 2018;59(2):68–75. DOI: 10.1159/000484091
41. Gross J., Glassman A., Jampol L. Writing Committee for the Diabetic Retinopathy Clinical Research N. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–2146. DOI: 10.1001/jama.2015.15217
42. Wubben T., Johnson M. Anti-VEGF Treatment Interruption Study Group. AntiVEGF therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions. Am J Ophthalmol. 2019;204:13–18. DOI: 10.1016/j.ajo.2019.03.005
43. Machemer R., Buettner H., Norton E., Parel J. Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol. 1971;75(4):813–820.
44. Khan M., Kuley A., Riemann C. Long-term visual outcomes and safety profile of 27-gauge pars plana vitrectomy for posterior segment disease. Ophthalmology. 2018;125(3):423–431. DOI: 10.1016/j.ophtha.2017.09.013
45. Yokota R., Inoue M., Itoh Y. Comparison of microinsicion vitrectomy and conventional 20-gauge vitrectomy for severe proliferative diabetic retinopathy. Jpn J Ophthalmol. 2015;59(5):288–294. DOI: 10.1007/s10384-015-0396-y
46. Rizzo S., Fantoni G., Mucciolo D. Ultrasound in vitrectomy an alternative approach to traditional vitrectomy techniques. Retina. 2020;40(1):24–32. DOI: 10.1097/IAE.0000000000002354
47. Berrocal M., Acaba L., Chenworth M. Surgical Innovations in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy. Current Diabetes Reports. 2019;19(10):106. Accessed September 16, 2019. DOI: 10.1007/s11892-019-1210-x
48. Smiddy W., Flynn H. Vitrectomy in the management of diabetic retinopathy. Surv Ophthalmol. 1999;43(6):491–507. DOI: 10.1016/s0039-6257(99)00036-3
49. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol. 1985;103:1644–1652.
50. Browning D., Lee C., Stewart M., Landers M. Vitrectomy for center-involved diabetic macular edema. Clin Ophthalmol. 2016;10:735–742. DOI: 10.2147/OPTH.S104906
51. Silva P., Diala P., Hamam R. Visual outcomes from pars plana vitrectomy versus combined pars plana vitrectomy, phacoemulsification, and intraocular lens implantation in patients with diabetes. Retina. 2014;34(10):1960–1968. DOI: 10.1097/IAE.0000000000000171
52. Sharma T., Fong A., Lai T. Surgical treatment for diabetic vitreoretinal diseases: a review. Clin Exp Ophthalmol. 2016;44(4):340–354. DOI: 10.1111/ceo.12752
53. Konovalova K.I., Shiskin M.M., Fayzrakhmanov R.R. Effectivness of multistage surgical treatment of advanced proliferative diabetic retinopathy complicated with primary cataract. Annals of Ophthalmology = Vestnik oftal’mologii. 2020;136(6-2):171–176 (In Russ.). DOI: 10.17116/oftalma2020136062171
54. Gupta B., Sivaprasad S., Wong R. Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: The Drive UK study. Eye (Lond). 2012;26:510–516. DOI: 10.1038/eye.2011.321
55. Iyer S., Regan K., Burnham J. Surgical management of diabetic tractional retinal detachments. Surv Ophthalmol. 2019;64(6):780–809. DOI: 10.1016/j.survophthal.2019.04.008
56. Stewart M., Browning D., Landers M. Current management of diabetic tractional retinal detachments. Indian J Ophthalmol. 2018;66(12):1751–1762. DOI: 10.4103/ijo.IJO_1217_18
57. Kikushima W., Imai A., Hirano T. Quick Referral and Urgent Surgery to Preempt Foveal Detachment in Retinal Detachment Repair. Asia Pac J of Ophthalmol. 2014;3(3):141–145. DOI: 10.1097/APO.0b013e3182a81240
58. Brănişteanu D., Bilha A., Moraru A. Vitrectomy surgery of diabetic retinopathy complications. Rom J Ophthalmol. 2016;60(1):31–36.
59. Hu X., Liu H., Wang L. Efficacy and safety of vitrectomy with internal limiting membrane peeling for diabetic macular edema: a meta-analysis. Int J Ophthalmol. 2018;11(11):1848–1855. DOI: 10.18240/ijo.2018.11.18
60. Jackson T., Nicod E., Angelis A. Pars plana vitrectomy for diabetic macular edema. A Systematic Review, Meta-Analysis, and Synthesis of Safety Literature. Retina. 2017;37(5):886–895. DOI: 10.1097/IAE.0000000000001280
61. Simunovic M., Hunyor A., Ho I. Vitrectomy for diabetic macular edema: a systematic review and meta-analysis. Can J Ophthalmol. 2014;49(2):188–195. DOI: 10.1016/j.jcjo.2013.11.012
62. Adelman R., Parnes A., Michalewska Z. Strategy for the management of diabetic macular edema: the European vitreo-retinal society macular edema study. BioMed Research International. 2015; 2015:352487. DOI: 10.1155/2015/352487
63. Farouk M., Naito T., Sayed K. Outcomes of 25-gauge vitrectomy for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2011;249:369–376. DOI: 10.1007/s00417-010-1506-7
64. Chen W., Lin C., Ko P. In vivo confocal microscopic findings of corneal wound healing after corneal epithelial debridement in diabetic vitrectomy. Ophthalmology. 2009;116:1038–1047. DOI: 10.1016/j.ophtha.2009.01.002
65. Holekamp N., Bai F., Shui Y. Ischemic diabetic retinopathy may protect against nuclear sclerotic cataract. Am J Ophthalmol. 2010;150(4):543–550. DOI: 10.1016/j.ajo.2010.05.013
66. Khuthaila M., Hsu J., Chiang A. Postoperative vitreous hemorrhage after diabetic 23-gauge pars plana vitrectomy. Am J Ophthalmol. 2013;155(4):757–763. DOI: 10.1016/j.ajo.2012.11.004
67. Lee B., Yu H. Vitreous hemorrhage after the 25-gauge transconjunctival sutureless vitrectomy for proliferative diabetic retinopathy. Retina. 2010;30(10):1671–1677. DOI: 10.1097/IAE.0b013e3181dcfb79
68. Jackson T., Johnston R., Donachie P. The Royal College of Ophthalmologists’ national ophthalmology database study of vitreoretinal surgery: Report 6, diabetic vitrectomy. JAMA Ophthalmology. 2016;134(1):79–85. DOI: 10.1001/jamaophthalmol.2015.4587
69. Ehrlich R., Goh Y., Ahmad N., Polkinghorne P. Retinal breaks in small-gauge pars plana vitrectomy. Am J Ophthalmol. 2012;153(5):868–872. DOI: 10.1016/j.ajo.2011.10.015
70. Koreen L., Yoshida N., Escariao P. Incidence of risk factors for, and combined mechanism of late-onset openangle glaucoma after vitrectomy. Retina. 2012;32(1):160– 167. DOI: 10.1097/IAE.0b013e318217fffb
71. Lalezary M., Kim S.J., Jiramongkolchai K., Recchia F.M., Agarwal A., Sternberg J.P. Long-term trends in intraocular pressure after pars plana vitrectomy. Retina. 2011;31(4):679–685. DOI: 10.1097/IAE.0b013e3181ff0d5a
72. Yau G., Silva P., Arrigg P. Postoperative Complications of Pars Plana Vitrectomy for Diabetic Retinal Disease. Semin Ophthalmol. 2018;33(1):126–133. DOI: 10.1080/08820538.2017.1353832
73. Tao Y., Jiang Y., Li X. Long-term results of vitrectomy without endotamponade in proliferative diabetic retinopathy with tractional retinal detachment. Retina. 2010;30:447–451. DOI: 10.1097/IAE.0b013e3181d374a5
74. Rodríguez M., Pérez S., Mena-Mollá S. Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies. Oxid Med Cell Longev. 2019;2019:4940825. DOI: 10.1155/2019/4940825
75. Mitchell P., Bandello F., Schmidt-Erfurth U. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625. DOI: 10.1016/j.ophtha.2011.01.031
76. Bressler S.B., Melia M., Glassman A.R. Diabetic Retinopathy Clinical Research Network. Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy before anti-vascular endothelial growth factor therapy. Retina. 2015;35:2516–2528. DOI: 10.1097/IAE.0000000000000617
77. Laugesen C., Ostri C., Brynskov T. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes. Acta Ophthalmol. 2017;95(1):28–32. Accessed July 30, 2016. DOI: 10.1111/aos.13160
78. Elhamid A., Mohamed A., Khattab A. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial. BMC Ophthalmol. 2020;20(1):130. Accessed April 6, 2020. DOI: 10.1186/s12886-020-01401-4
Review
For citations:
Petrachkov D.V., Korobov E.N., Arzhukhanov D.D. Role of Vitrectomy in the Treatment of Diabetic Retinopathy. Ophthalmology in Russia. 2021;18(3S):718-726. (In Russ.) https://doi.org/10.18008/1816-5095-2021-3S-718-726
Views:
714
Email this article 